Premium
Comparison of COBE® Spectra™ software version 4.7 PBSC and version 6.0 auto PBSC™ program
Author(s) -
Wilke Richard,
Brettell Mary,
Prince H. Miles,
Wolf Max,
McKenna Rosemary,
Serpell Elizabeth,
Molloy Marjorie,
Stevens Helen,
Quinn Midge,
Gates Priscilla,
Chapple Peter
Publication year - 1999
Publication title -
journal of clinical apheresis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.697
H-Index - 46
eISSN - 1098-1101
pISSN - 0733-2459
DOI - 10.1002/(sici)1098-1101(1999)14:1<26::aid-jca5>3.0.co;2-1
Subject(s) - apheresis , medicine , cd34 , nuclear medicine , peripheral blood mononuclear cell , hemoglobin , platelet , leukapheresis , stem cell , biochemistry , chemistry , biology , in vitro , genetics
Until recently, the collection of peripheral blood progenitor cells (PBPC) has been semi‐automated by using the COBE® Spectra™, with the operator manually maintaining the position of the white cells being collected. The COBE® Spectra™ Version 6.0 apheresis device offers the user an automated program for the collection of PBPC. In this study, we compared the new software Version 6.0 to that of Version 4.7. Patients (n=46) undergoing PBPC collection were allocated to cell processing with either Version 4.7 (n=24) or Version 6.0 (n=22). The CD34+ cell count, mononuclear cell (MNC) count, white cell count (WCC), hemoglobin (Hb), and platelet content in the autograft product by using the two versions were compared. We divided the analysis into three subsets according to peripheral blood (PB) CD34 content: <10×10 6 /L, 10–50×10 6 /L and >50×10 6 /L. Analysis of the three subsets showed no statistical difference between results obtained when the starting PB CD34+ cell count was 10–50×10 6 /L ( P =0.08) or >50 ×10 6 /L ( P =0.4065). At lower starting PB CD34+ cell counts of <10×10 6 /L, Version 4.7 was superior ( P =0.0167). However, autograft platelet contamination of the autograft was significantly higher using Version 4.7 ( P =<0.0001). J. Clin. Apheresis 14:26–30, 1999. © 1999 Wiley‐Liss, Inc.